Biochemical Effects and Toxicity of Mitoxantrone in Cultured Heart Cells
In response to the cumulative cardiotoxicity associated with the clinical use of the antitumor agent doxorubicin, many structurally related anthraquinone drugs have been developed. Mitoxantrone has been the most successful of these, and is used with increasing frequency in the treatment of leukemia, lymphoma, and breast cancer. Response rates are similar to those obtained with doxorubicin treatment, and notably, mitoxantrone is less cardiotoxic. However, while more courses of mitoxantrone therapy can be given, patients eventually develop a cumulative cardiotoxicity which is clinically similar to that observed following prolonged doxorubicin treatment (Henderson et al., 1989).
KeywordsCovalent Binding Heart Cell Malondialdehyde Level Culture Heart Cell Mitoxantrone Therapy
Unable to display preview. Download preview PDF.